| Name | 3-(1,3-benzodioxol-5-yl)-5-hydroxy-5-(4-methoxyphenyl)-4-[(3,4,5-trimethoxyphenyl)methyl]furan-2-one |
|---|---|
| Synonyms |
PPADS tetrasodium salt
CI 1020 |
| Description | CI-1020 (PD156707) is an orally active and selective antagonist targeting endothelin (ETA) with an IC50 value of 0.3 nM. CI-1020 blocks intimal hyperplasia in human saphenous veins completely in organ culture. CI 1020 inhibits hypoxic pulmonary hypertension and blocks ET-1-induced pressor responses following oral administration[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
ETA:0.3 nM (IC50) |
| References |
| Density | 1.351g/cm3 |
|---|---|
| Boiling Point | 722.338ºC at 760 mmHg |
| Molecular Formula | C28H26O9 |
| Molecular Weight | 506.50 |
| Flash Point | 242.505ºC |
| Exact Mass | 506.15800 |
| PSA | 101.91000 |
| LogP | 3.84810 |
| Vapour Pressure | 0mmHg at 25°C |
| Index of Refraction | 1.623 |
|
~%
162256-50-0 |
| Literature: Journal of Medicinal Chemistry, , vol. 42, # 12 p. 2162 - 2168 |
|
~%
162256-50-0 |
| Literature: Journal of Medicinal Chemistry, , vol. 42, # 12 p. 2162 - 2168 |
|
~%
162256-50-0 |
| Literature: Journal of Medicinal Chemistry, , vol. 38, # 8 p. 1259 - 1263 |
|
~%
162256-50-0 |
| Literature: Journal of Medicinal Chemistry, , vol. 42, # 12 p. 2162 - 2168 |
| Precursor 3 | |
|---|---|
| DownStream 0 | |